Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Silverman

Showing results (741-750 of 816) with videos related to

Pageof 82
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 26, 2011
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL ConsortiumLynda M Vrooman, Donna S Neuberg, Kristen E Stevenson, et al.
Hospital Pediatrics|January 19, 2024
Inequitable Poverty Exposures: A Subspecialty Opportunity to Address DisparitiesKristine A Karvonen, Puja J Umaretiya, Victoria B Koch, et al.
Pediatric Blood & Cancer|June 8, 2018
Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001Uma H Athale, Maneka Puligandla, Kristen E Stevenson, et al.
Blood Advances|January 26, 2021
Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohortSong Yao, Qianqian Zhu, Peter D Cole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomesSteven E Lipshultz, Tracie L Miller, Rebecca E Scully, et al.
Pediatric Blood & Cancer|January 11, 2018
Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemiaM L Sulis, T M Blonquist, K E Stevenson, et al.
JACC. Cardiovascular Interventions|November 23, 2013
Long-term experience and outcomes with transcatheter closure of patent foramen ovaleIgnacio Inglessis, Sammy Elmariah, Pablo A Rengifo-Moreno, et al.
Pediatric Blood & Cancer|April 26, 2018
Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemiaMaria Luisa Sulis, Traci M Blonquist, Kristen E Stevenson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 4, 2025
Treatment-related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration During Therapy for Childhood Acute Lymphoblastic LeukemiaYongkyu Park, Nirajan K C, Jeremy Willekens, et al.
Blood|September 1, 2011
The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemiaAlejandro Gutierrez, Alex Kentsis, Takaomi Sanda, et al.
Pageof 82

Showing results (741-750 of 816) with videos related to

Sort By:
Pageof 82
European Journal of Cancer (Oxford, England : 1990)|April 26, 2011
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL ConsortiumLynda M Vrooman, Donna S Neuberg, Kristen E Stevenson, et al.
Hospital Pediatrics|January 19, 2024
Inequitable Poverty Exposures: A Subspecialty Opportunity to Address DisparitiesKristine A Karvonen, Puja J Umaretiya, Victoria B Koch, et al.
Pediatric Blood & Cancer|June 8, 2018
Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001Uma H Athale, Maneka Puligandla, Kristen E Stevenson, et al.
Blood Advances|January 26, 2021
Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohortSong Yao, Qianqian Zhu, Peter D Cole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomesSteven E Lipshultz, Tracie L Miller, Rebecca E Scully, et al.
Pediatric Blood & Cancer|January 11, 2018
Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemiaM L Sulis, T M Blonquist, K E Stevenson, et al.
JACC. Cardiovascular Interventions|November 23, 2013
Long-term experience and outcomes with transcatheter closure of patent foramen ovaleIgnacio Inglessis, Sammy Elmariah, Pablo A Rengifo-Moreno, et al.
Pediatric Blood & Cancer|April 26, 2018
Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemiaMaria Luisa Sulis, Traci M Blonquist, Kristen E Stevenson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 4, 2025
Treatment-related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration During Therapy for Childhood Acute Lymphoblastic LeukemiaYongkyu Park, Nirajan K C, Jeremy Willekens, et al.
Blood|September 1, 2011
The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemiaAlejandro Gutierrez, Alex Kentsis, Takaomi Sanda, et al.
Pageof 82